Vincristine sulfate

目录号:S1241 别名: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate通过与微管蛋白结合而抑制微管聚合,IC50为32 μM。

规格 价格 库存 购买数量  
RMB 582.05 现货
RMB 2229.59 现货
RMB 7118.45 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的2个实验数据:

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

    for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

产品安全说明书

Microtubule Associated抑制剂选择性比较

生物活性

产品描述 Vincristine sulfate通过与微管蛋白结合而抑制微管聚合,IC50为32 μM。
靶点
Microtubules [1]
(Cell-free assay)
32 μM
体外研究

Vincristine抑制微管蛋白二聚体聚合亚单位,抑制它们的聚合作用,Ki为85 nM。[1]在低浓度时,Vincristine抑制纺锤体,使染色体分离失败,进而导致中期停滞,并抑制有丝分裂。在较高浓度时,Vincristine可能干扰且诱导全部微管解聚。[2] Vincristine 诱导肿瘤细胞凋亡,且抑制SH-SY5Y细胞增殖,IC50为0.1 µM。Vincristine诱导有丝分裂停滞,促进caspase-3和-9及cyclin B的表达,但降低cyclin D的表达。[3] Vincristine通过干扰微管功能而诱导神经毒性形成,这会导致轴突运输堵塞,从而导致轴突变性。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 MXnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUG4N40zOC1yLkWg{txO MX2yOEBp NVT0cnhJ\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm= NX7T[Y5vOjV4NkO3Olk>
HepG2-HBV1.1 MX3BdI9xfG:|aYOgRZN{[Xl? NHjq[|gxNTBwNTFOwG0> MoW0NlQhcA>? M{jIWIlv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= NYfhVZc{OjV4NkO3Olk>
HepG2.2.15 MoDTSpVv[3Srb36gRZN{[Xl? M2f6VlAvOSEQvF2= M3LYd|I1KGh? MVLwdo9ud3SnczDo[ZBifGm2aYOgRkB3cXK3czDwdo91\WmwIHX4dJJme3Orb36= NXLNXpF6OjV4NkO3Olk>
HepG2-HBV1.1 NHXpeWxHfW6ldHnvckBCe3OjeR?= M3i3O|AvOSEQvF2= NETRNIEzPCCq M4fLNZBzd22xdHXzJIhmeGG2aYTpd{BDKH[rcoXzJJBzd3SnaX6g[ZhxemW|c3nvci=> Mn\0NlU3PjN5Nkm=
HepG2-HBV1.1 M{nZUGZ2dmO2aX;uJGF{e2G7 NGDve5gxNjFizszN M3L4cVQ5KGh? MojWdJJwdW:2ZYOgZ4VtdCCneHPy[ZRqd25ib3[gbIVx[XSrdHnzJGIhfmm{dYOgcpVkdGWxY3Hwd4lleyCrboP0[YFlKG:oIHjldIF1cXSrczDCJJZqenW|IFThcoUheGG{dHnjcIV{ M1P2flI2PjZ|N{[5
HepG2-HBV1.1 NFnWXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrvcmcxNjFizszN M4CwclEuPSCm MmDJbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36geIlu\SCmZYDlcoRmdnSueR?= M3m0b|I2PjZ|N{[5
HepG2-HBV1.1 NGjzNnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD1d5pCOC5zIN88US=> MYixMVUh\A>? NFr3Z|JqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckB1cW2nIHTldIVv\GWwdHz5 NXPzN40yOjV4NkO3Olk>
HepG2-HBV1.1 M2HQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mny4NE4yKM7:TR?= MYGxNk04OiCq NUPXV2NDcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCVLYDoZZNm MViyOVY3Ozd4OR?=
HepG2-HBV1.1 NUH2N4RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrM[FQxNjFizszN MnnpNVIuPzJiaB?= NGCwfnFqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U> MoG3NlU3PjN5Nkm=
Raji MmrQSpVv[3Srb36gRZN{[Xl? MnLiNE42yqEQvF2= NYPQeZhCPzJiaB?= NUnaSY1V[WKxbHnzbIV{KGG3dH;wbIFogcLi M{\GU|I2PDR4M{e3
SK-MEL-28  MXTGeY5kfGmxbjDBd5NigQ>? NYLCUIhiOzBibl2= MV62JIg> NIHycItqdmS3Y3XzJGcz6oDVTTDj[YxtNWO7Y3zlJIFzemW|dB?= NXvIT|YzOjV|MUOwNVA>
H157 NH\Rd3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXOTVJGUUN3ME2xMlA{KMLzIECuNFQhdWm3Ml2= M{Ho[VI2OjV5OUGx
Jurkat NHzEfWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjTXWo1OS1|IH7N MUe0POKhcA>? MW\EUXNQ NIrydWJl\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6 M{XMVVI2OTV4MUS2
CEM NWLzO5FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUSxMVMhdk1? M2LPU|Q5yqCq M{fpPGROW09? NXXYc3c3\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? NXKxRZlSOjVzNU[xOFY>
P12 MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzvXXdvOS1|IH7N NUPmfnpTPDkEoHi= MYLEUXNQ M3jCWIRm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk> MlnFNlUyPTZzNE[=
KB MmnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXPfplKSzVyPUCuNFA1QSEEsTCwMlAxODFizszN NFX0SYkzPTB3OEWyOi=>
KBv200 (ABCB1) NXKwWpNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDt[2JQUUN3ME2wMlM1PjJiwsGgNE4xODZ4IN88US=> NGX1b|gzPTB3OEWyOi=>
SUDHL6  MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrMPWwy6oDLzszN NVrFSIlpPDhxN{KgbC=> NXvWZ4Y4cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NHrSTnQzPDl4MU[wOC=>
SUDHL6  NFW3PI9HfW6ldHnvckBCe3OjeR?= NETucVky6oDLzszN NXLxfWQzPzJiaB?= MYPpcoR2[2W|IIPp[45q\mmlYX70JIFxd3C2b4TpZ{Bud3KyaH;sc4d6KGOqYX7n[ZMh[2:2cnXzeIVlKHerdHigRmNNOTGDIIPpVm5C Mn;ENlQ6PjF4MES=
HCT-116 NWnyNFdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zm[mdKPTB;NTDuUS=> NEi4TJQzPDl{N{i1Oy=>
SKNBe2C Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvldlNKSzVyPUOyMljDuTRwMDDuUS=> M4HHflI1QTJzOUKw
IGNR91 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPmTZlKSzVyPUK0MlPDuTFwNzDuUS=> M4XMVlI1QTJzOUKw
SKNAS M2\1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTFwNdMxNE4zKG6P MnPXNlQ6OjF7MkC=
LAN1 NUmwV|l4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTJwM9MxNE4zKG6P MX2yOFkzOTl{MB?=
SHSY5Y MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTETWM2OD16LkNCtVAvPiCwTR?= MonGNlQ6OjF7MkC=
A549-WT NUDiZVVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvrOlBTUUN3ME2xPU41OzdiwsGgNE42QTRiIH7N MmrXNlQ5PTh6Mke=
A549-R NUPSOVhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HyS2lEPTB;MUKuNVc5KMLzIECuN|M{KCCwTR?= NHq2VnUzPDh3OEiyOy=>
MCF-7-WT MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rGeGlEPTB;MUeuO|UzKMLzIECuNlE5KCCwTR?= M4nSe|I1QDV6OEK3
MCF-7-R MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfze4pKSzVyPUWuOVM6KMLzIECuNVQ1KCCwTR?= NUDpdFh5OjR6NUi4Nlc>
A549-R M2e5cmN6fG:2b4jpZ4l1gSCDc4PhfS=> NEfDVItKSzVyPUGyMlE4QCEEsTCwMlM{OyCwTR?= M2fjVFI1QDV6OEK3
MCF-7-R MVHDfZRwfG:6aXPpeJkhSXO|YYm= M1fzd2lEPTB;NT61N|khyrFiMD6xOFQhdk1? NWP3SoU4OjR6NUi4Nlc>
SW620 NH\lTINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHrcIhrUUN3ME23MlgxKMLzIECuNFghdk1? MljHNlQ4OjZ5M{m=
SW620/AD300 NUjL[XNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInSU4lKSzVyPUmwPU43OCEEsTC4MlkyKG6P M1zPWlI1PzJ4N{O5
HEK293/pcDNA3.1 NUDoXVRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTFwNEWgxtEhOC5{MDDuUS=> NYPSVGI6OjR5Mk[3N|k>
HEK293/ABCC1 MmPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:1c2lEPTB;MUmuNlkhyrFiMj6wPEBvVQ>? MYCyOFczPjd|OR?=
TCC NWnocpJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWWyOEBp MmfMTWM2OD15MDDuUS=> MlXVNlQ4OTZ7NES=
TCC NYDzXVZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[0PEBp M2HUPWlEPTB;NUCgcm0> M{L3W|I1PzF4OUS0
HepG2/ADM M2jRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJwN{i2N:KyOC5{M{exJO69VQ>? M{nFRVI1PzB2NUW2
HepG2 NWXyfIo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMEGxOeKyOC5yMEG3JO69VQ>? NUHZVZEzOjR5MES1OVY>
MCF-7/ADR NYTJ[IZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTRwNEiyOuKyOC5{MEewJO69VQ>? MkTJNlQ4ODR3NU[=
MCF-7 NInreFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi1SFVqUUN3ME2wMlAyPToEsUCuNFA3OiEQvF2= Ml7qNlQ4ODR3NU[=
A-172  MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlv0NE4yyqEQvF2= MnzTNlQwPzJiaB?= NGexcJlqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6 NInqXGMzPDV|MEKzOS=>
U-251MG M4O0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYWwMlHDqM7:TR?= NITOTW0zPC95MjDo M1:0eIlvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWg[IVx\W6mZX70cJk> NX[4R|I3OjR3M{CyN|U>
DLD-1 NGrpV2FHfW6ldHnvckBCe3OjeR?= NHfaNpMyODBibl2= NF7udGQ1QCCq MVLwdo9ud3SnczDSWW5ZOyCmZX3leIh6dGG2aX;uxsA> M3fzZlI1PDB|NEWz
CCD18Co Mny5SpVv[3Srb36gRZN{[Xl? NUDFVnh{OTByIH7N NHzTfnQ1QCCq NXXWT5FpeHKxbX;0[ZMhWlWQWEOg[IVu\XSqeXzheIlwdsLi NH\Tc4gzPDRyM{S1Ny=>
DLD-1 M2G3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfPR2MxNTFyMECgcm0> MVi0PEBp MXXpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NFrGTJgzPDRyM{S1Ny=>
CCD18Co NEXUcHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOwMVExODBibl2= M4C0XVQ5KGh? NXfhUI1ScW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NU\iVHZZOjR2MEO0OVM>
HepG2 M{jFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m5TFI1KGh? MWHJR|UxRTV{LkZihKnPxE1? NWG3bZBoOjR|NEG2PFg>
HEK293/pcDNA3.1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz5TWM2OD1yLkCwOOKyOC5yMECzJO69VQ>? Mn\UNlQzQDR5OEO=
HEK293/MRP1 NFLUSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;4TWM2OD1yLkC1OeKyOC5yMUKwJO69VQ>? NFqwbm8zPDJ6NEe4Ny=>
Ramos MYXBdI9xfG:|aYOgRZN{[Xl? M3nleFLjiIoQvF2= MkHLOFghcA>? NUPRfmJKcW6mdXPld{A{PC54JdMxNU46OiViYYDvdJRwe2m| M3ryb|I1OjV4NEmx
NCI-H1299/pcDNA3 MVPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHvkd|QxNTJyIH7N M33ZeFk3KGh? MWDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MmS1NlQyPzdyMUK=
H1299/ICAM-3 M3PoNmNmdGxiVnnhZoltcXS7IFHzd4F6 NUnWfVlVOC1{MDDuUS=> MmHSPVYhcA>? M3X6V4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NV;FUZR6OjRzN{ewNVI>
NCI-H1299/pcDNA3 NGW0SolHfW6ldHnvckBCe3OjeR?= MXuxM|UwOTBxMkFCpI5O M1fZe|k3KGh? Mo\lbY5lfWOnczDjcIVifmGpZTDv[kBk[XOyYYPld{0{NCB6LDC5MEBidmRiUFHSVC=> MVKyOFE4PzBzMh?=
H1299/ICAM-3 M1L1UWZ2dmO2aX;uJGF{e2G7 NIPNVo4yNzVxMUCvNlDDqG6P MU[5OkBp MnXXbY5lfWOnczDjcIVifmGpZTDv[kBk[XOyYYPld{0{NCB6LDC5MEBidmRiUFHSVC=> MmTmNlQyPzdyMUK=
W1 M{DLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMECzNkDPxE1? NWTrOlFLOjRzNECxO|Y>
W1VR NXjvco9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXO0eYtiUUN3ME2wMlA2PiEQvF2= NGLKc20zPDF2MEG3Oi=>
K562 M1H2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMEOyJOKyKDBwMECxJEDPxE1? MkjUNlQyOzV7M{e=
K562/ADR NYjJfnNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDVWWxLUUN3ME2zMlI3OSEEsTCwMlQyOiEQvF2= NHXaZogzPDF|NUmzOy=>
K562 MU\BdI9xfG:|aYOgRZN{[Xl? M2DQPFAvOyEQvF2= Ml\6NlQhcA>? MkXRbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? MXSyOFE{PTl|Nx?=
K562/ADR NHf1[XZCeG:ydH;zbZMhSXO|YYm= NUC4OXVQOyEQvF2= NVPVUJE3OjRiaB?= NIO5SppqdmS3Y3XzJIFxd3C2b4Ppdy=> NUfkTGw{OjRzM{W5N|c>
A549 M2rGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwMUCgxtEhOC5yMzFOwG0> M{fMPVI{QTdzMEe1
K562 M{TabmNmdGxiVnnhZoltcXS7IFHzd4F6 NETlVXQ{Njd34pETOlDDqG6P NHuxXmU4OsLiaNMg M1\QV4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MlnCNlM5Pzd{MkO=
lucena NYnJelhoS2WubDDWbYFjcWyrdImgRZN{[Xl? NIXEeWc{Njd34pETOlDDqG6P MYC3NuKhcMLi M4mxSY5wKGWoZnXjeC=> NU\sTlhXOjN6N{eyNlM>
FEPS MVLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NULVZY42Oy55NfMAl|YxyqCwTR?= MV:3NuKhcMLi MWruc{Bm\m[nY4S= MnS1NlM5Pzd{MkO=
A2780 NFjleFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj1TWM2OD1|LkWgcW0> MXKyN|gzQTJyMx?=
ACHN MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrMeGQ{UUN3MEywMlEhdU1? M1PCfVI{QDJ7MkCz
U-937 M2XoOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nne2lEPTB:M{Sgcm0> NF3yNmwzOzh{OUKwNy=>
Jurkat M3G4dmFxd3C2b4Ppd{BCe3OjeR?= MVm1xsDPxGdxbX|CpC=> NHPDNXEzPCCq Moi3bY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? MV:yN|gyODRyOR?=
Jurkat NGO0V5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;DRW42yqEQvHevcYzDqA>? MUKyOEBp NH71WWNienKnc4SgTpVzc2G2IHPlcIx{KGmwIFeyM20heGijc3W= M1L0[|I{QDFyNEC5
Hep-2 NVzkWm5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrxV21KSzVyPUCuNFTDuTBwMEGg{txO NGPWTZEzOzd6MESyOC=>
Hep-2/v MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\Ib|JKSzVyPUGuPOKyOC5{MDFOwG0> MnTINlM4QDB2MkS=
SGC-7901 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfxNXIxNTFyIN88[{9udA>? M2jpfFI1NzR6L{eyJIg> NFPxWZZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MnfYNlM4PDN3N{K=
SGC-7901/VCR NGfvS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfKc|BEOC1zMDFOwIcwdWx? NUH0bpVGOjRxNEivO|IhcA>? MXPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NVjJeYJtOjN5NEO1O|I>
SGC-7901 NHr3R2lCeG:ydH;zbZMhSXO|YYm= MmXNbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? MlP5NlM4PDN3N{K=
SGC-7901/VCR NGe1SGxCeG:ydH;zbZMhSXO|YYm= NIjjbldqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 NE\kRYIzOzd2M{W3Ni=>
KB-3-1 NFf5[WJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF23fYxKSzVyPUGuOlYhyrFiMD6xOlIh|ryP MlnONlM3PzN2NEW=
KB-C2 NUHuWXJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlewTWM2OD1{MEKuOVYhyrFiNEKuOFgyKM7:TR?= Ml\vNlM3PzN2NEW=
KB-3-1 NUXjZ5pST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTFwMk[gxtEhOC5yMkeg{txO MUSyN|Y4OzR2NR?=
KB-V1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJyOD64OUDDuSB{MD60JO69VQ>? NWXCUXVXOjN4N{O0OFU>
HEK293/pcDNA3.1 NWjYWHhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXjTWM2OD1{ND6xJOKyKDBwMkC0JO69VQ>? M3PmWVI{Pjd|NES1
HEK293/ABCB1 M3y4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi5[YZKSzVyPUO1NVIvQCEEsTCzO|gvOzlzIN88US=> MXKyN|Y4OzR2NR?=
A549/EGFP  NHPGPIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17UfFAvODFvMUCwNEDPxE1? M{PPOmlEPTB;OE[uO{DDuSB{OT6xJO69VQ>? MmnkNlM3OzR{OEK=
A549/Slug NWS5dokxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXrS2MxNjBzLUGwNFAh|ryP NFjISZFKSzVyPUmuO{DDuSB|LkGg{txO MUWyN|Y{PDJ6Mh?=
JFCR39  MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnMNUDDvU1? NVfNZWpSOjRiaB?= NWXj[4dITE2VTx?= NVThVpgydWG{a3XkcJkhcW6lcnXhd4V{KHSqZTDueY1j\XJib3[gS|IwVSCyaHHz[UBk\Wyucx?= NFO0fW8zOzV7OEK3Oi=>
A549 NUX2U5I{TnWwY4Tpc44hSXO|YYm= MWOxNFAhdk1? M2fSN|E3KGh? NWLhWWx5TE2VTx?= M2S0Soxm[WS|IITvJIEhdG:|czDv[kBucWO{b4T1ZpVt\XN? NHvFWoUzOzV7OEK3Oi=>
SGC7901 NYG4fXZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXjTWM2OD1zLkK25qCKyrIkgJmwMlEyKM7:Zz;tcC=> M4fkdVI{PTZ2NEiy
SGC7901/LV-NC M{DmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXGOFJpUUN3ME2xMlc46oDLwsJihKkxNjF4IN88[{9udA>? MXSyN|U3PDR6Mh?=
SGC7901/LV-SGO1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlftTWM2OD12LkO25qCKyrIkgJmwMlM4KM7:Zz;tcC=> NFHSVnYzOzV4NES4Ni=>
SGC7901/VCR M1LwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nPZmlEPTN;MkCuOVPjiIoEsfMAjVEvQTZizsznM41t M4\5bVI{PTZ2NEiy
SGC7901/VCR-NC MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;kO5FzUUN3ME2xPU45PuLCidMx5qCKOi5yMTFOwIcwdWx? MUmyN|U3PDR6Mh?=
SGC7901/VCR-si-SGO1 M4nWTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfjTJJKSzVyPU[uNVjjiIoEsfMAjVEvODNizsznM41t NWXtcJczOjN3NkS0PFI>
SGC7901/ADR M1exbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfCcGFXUUN3ME23Mlg26oDLwsJihKkxNjZ2IN88[{9udA>? NIj1N5QzOzV4NES4Ni=>
SGC7901/ADR-NC MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rVVGlEPTB;OD65N-KBkcLz4pEJNE43QCEQvHevcYw> NEm3bW0zOzV4NES4Ni=>
SGC7901/ADR-si-SGO1 NFXHZnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS4XnVvUUN3ME2zMlQ36oDLwsJihKkxNjJ7IN88[{9udA>? MYKyN|U3PDR6Mh?=
SH-SY5Y  MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3faTVAvODBzLUGwJO69VQ>? NHPyc|czPCCq M2G1e2lEPTB;MD6xNVPDuTBwMEGyJO69VQ>? MU[yN|EzQTB4NR?=
SH-SY5Y  MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkGyNE4xODFvMUCg{txO M3\uOlQ5KGh? M17SZmlEPTB;MD6wO|jDuTBwMEC5JO69VQ>? M{nkWVI{OTJ7ME[1
SH-SY5Y  NGT4bVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH2dndWOC5yMEGtNVAh|ryP NEfDS204OiCq NEK2fHlKSzVyPUCuNFUyyrFyLkCwPEDPxE1? M1XtdlI{OTJ7ME[1
SH-SY5Y NE[2PIZCeG:ydH;zbZMhSXO|YYm= Mn;ENE4yKM7:TR?= MlfTNE0zPCCq Mo\LbY5lfWOnczDhdI9xfG:|aYOgc4YhW0hvU2m1XUBk\WyuczDmc4xtd3erbnegZ4VtdCCleXPs[UBienKnc4SgZZQhfGinIFeyM20heGijc3W= M3roV|I{OTJ7ME[1
SH-SY5Y NHfNPYpCeG:ydH;zbZMhSXO|YYm= M2ryWFAvOSEQvF2= NXPQUolDOC1{NDDo NUfnUXpKcW6mdXPld{BucXSxdHnjJIFzemW|dNMg NUnGPIJnOjNzMkmwOlU>

... Click to View More Cell Line Experimental Data

体内研究 Vincristine 按3 mg/kg剂量单独腹腔注射给药携带双侧皮下移植瘤RH12或RH18的小鼠,平均生长延迟120天和52天以上,且再植指数分别为0.06%和5%。[5] Vincristine 处理小鼠,通过宿主细胞介导的血管效应及直接的微管蛋白介导的的细胞毒性作用而对皮下结肠38肿瘤起作用。Vincristine (5 mg/kg) 降低肿瘤血流量,降低近75%。[6]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
+ 展开
  • Cell lines: B16 黑色素瘤细胞
  • Concentrations: 10 nM
  • Incubation Time: 3 天
  • Method: 细胞按5 × 104 cells/mL的浓度接种在含2 mL培养基的35-mm 实验板上,在37°C下 含5% CO2 和95% 空气 的环境下生长24小时。然后使用有或无10 nM药物的新鲜培养基更换原来的培养基,继续增殖3天。使用胰蛋白酶和EDTA将细胞分离后,每天使用库氏计数器完成细胞计数
    (Only for Reference)
动物实验:[5]
+ 展开
  • Animal Models: 携带人类横纹肌肉瘤移植瘤Rh12的鼠
  • Formulation: 水溶液
  • Dosages: 3 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
Saline
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 923.04
化学式

C46H58N4O14S

CAS号 2068-78-2
稳定性 powder
in solvent
别名 Leurocristine

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03519984 Recruiting Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Blasts 5 Percent or More of Bone Marrow Nucleated Cells|Myelodysplastic/Myeloproliferative Neoplasm|Philadelphia Chromosome Positive|Recurrent Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelogenous Leukemia BCR-ABL1 Positive|Secondary Acute Myeloid Leukemia|T Acute Lymphoblastic Leukemia University of Southern California|National Cancer Institute (NCI)|Vasgene Therapeutics Inc|Whittier Foundation May 9 2018 Phase 1
NCT03136146 Recruiting Hematopoietic/Lymphoid Cancer|Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Burkitt Leukemia/Lymphoma M.D. Anderson Cancer Center August 9 2017 Phase 2
NCT01397825 Completed Diffuse Large B-Cell Lymphoma|Transformed Follicular Lymphoma|Mantle Cell Lymphoma|Burkitt''s Lymphoma Millennium Pharmaceuticals Inc.|Takeda August 9 2011 Phase 1|Phase 2
NCT02564484 Recruiting Leukemia|Lymphoma St. Jude Children''s Research Hospital|University of Chicago|National Cancer Institute (NCI) February 8 2016 --
NCT03399747 Enrolling by invitation Diffuse Large B-cell Lymphoma Asan Medical Center December 7 2016 Phase 2
NCT01527149 Active not recruiting Stage I Mantle Cell Lymphoma|Stage II Contiguous Mantle Cell Lymphoma|Stage II Non-Contiguous Mantle Cell Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Mantle Cell Lymphoma Roswell Park Cancer Institute|National Cancer Institute (NCI)|National Comprehensive Cancer Network December 6 2011 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • 回答:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

相关Microtubule Associated产品

Tags: 购买Vincristine sulfate | Vincristine sulfate供应商 | 采购Vincristine sulfate | Vincristine sulfate价格 | Vincristine sulfate生产 | 订购Vincristine sulfate | Vincristine sulfate代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID